Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Satish Garg to Blood Glucose

This is a "connection" page, showing publications Satish Garg has written about Blood Glucose.

 
Connection Strength
  
 
 
12.941
  
  1. Akturk HK, Karakus KE, Cengiz D, Mason E, Beck E, Kaur G, Garg SK. Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes. Diabetes Technol Ther. 2026 Mar; 28(3):193-200.
    View in: PubMed
    Score: 0.458
  2. Garg SK, Bailey TS, Castorino K, Christiansen MP, Liljenquist DR, Salazar H, Akturk HK, Gao S, Johnson ML, Beck SE. Accuracy of the 15.5-Day G7 iCGM in Adults with Diabetes. Diabetes Technol Ther. 2025 06; 27(6):430-438.
    View in: PubMed
    Score: 0.428
  3. Garg SK, Hirsch IB, Repetto E, Snell-Bergeon J, Ulmer B, Perkins C, Bergenstal RM. Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis. Diabetes Obes Metab. 2024 11; 26(11):5202-5210.
    View in: PubMed
    Score: 0.413
  4. Garg SK, Akturk HK, Kaur G, Beatson C, Snell-Bergeon J. Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes. Diabetes Technol Ther. 2024 06; 26(6):367-374.
    View in: PubMed
    Score: 0.402
  5. Garg SK. Past, Present, and Future of Continuous Glucose Monitors. Diabetes Technol Ther. 2023 06; 25(S3):S1-S4.
    View in: PubMed
    Score: 0.378
  6. Carroll J, Heverly J, Phillip M, Battelino T, Garg S. International Consensus of Continuous Glucose Monitor Use in Pharmacological Clinical Trials in Diabetes. Diabetes Technol Ther. 2023 04; 25(4):217-218.
    View in: PubMed
    Score: 0.371
  7. Garg SK, Shah V. Closed-loop insulin delivery systems for patients with diabetes. Lancet Digit Health. 2019 05; 1(1):e2-e3.
    View in: PubMed
    Score: 0.285
  8. Garg SK, Hirsch IB. Self-Monitoring of Blood Glucose. Diabetes Technol Ther. 2019 02; 21(S1):S4-S12.
    View in: PubMed
    Score: 0.280
  9. Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, Maahs DM, Tamborlane WV, Bergenstal R, Smith E, Olson BA, Garg SK. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther. 2019 02; 21(2):66-72.
    View in: PubMed
    Score: 0.279
  10. Akturk HK, Snell-Bergeon JK, Rewers A, Klaff LJ, Bode BW, Peters AL, Bailey TS, Garg SK. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. Diabetes Technol Ther. 2018 10; 20(10):639-647.
    View in: PubMed
    Score: 0.273
  11. Garg SK, Akturk HK. A New Era in Continuous Glucose Monitoring: Food and Drug Administration Creates a New Category of Factory-Calibrated Nonadjunctive, Interoperable Class II Medical Devices. Diabetes Technol Ther. 2018 06; 20(6):391-394.
    View in: PubMed
    Score: 0.268
  12. Wadwa RP, Laffel LM, Shah VN, Garg SK. Accuracy of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System During 10 Days of Use in Youth and Adults with Diabetes. Diabetes Technol Ther. 2018 06; 20(6):395-402.
    View in: PubMed
    Score: 0.268
  13. Akturk HK, Rewers A, Joseph H, Schneider N, Garg SK. Possible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes. Diabetes Technol Ther. 2018 06; 20(S2):S224-S232.
    View in: PubMed
    Score: 0.267
  14. Shah VN, Laffel LM, Wadwa RP, Garg SK. Performance of a Factory-Calibrated Real-Time Continuous Glucose Monitoring System Utilizing an Automated Sensor Applicator. Diabetes Technol Ther. 2018 06; 20(6):428-433.
    View in: PubMed
    Score: 0.267
  15. Garg SK, Hirsch IB. Self-Monitoring of Blood Glucose. Diabetes Technol Ther. 2018 02; 20(S1):S3-S12.
    View in: PubMed
    Score: 0.261
  16. Garg SK, Akturk HK. The Future of Continuous Glucose Monitoring. Diabetes Technol Ther. 2017 06; 19(S3):S1-S2.
    View in: PubMed
    Score: 0.250
  17. Garg SK, Akturk HK. Flash Glucose Monitoring: The Future Is Here. Diabetes Technol Ther. 2017 May; 19(S2):S1-S3.
    View in: PubMed
    Score: 0.248
  18. Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A, Cordero TL, Shin J, Lee SW, Kaufman FR. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2017 03; 19(3):155-163.
    View in: PubMed
    Score: 0.244
  19. Garg SK. The Future of Glucose Monitoring. Diabetes Technol Ther. 2016 Feb; 18 Suppl 2:S2iv-22.
    View in: PubMed
    Score: 0.228
  20. Garg SK, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, Shin J, Welsh JB, Kaufman FR. Hypoglycemia begets hypoglycemia: the order effect in the ASPIRE in-clinic study. Diabetes Technol Ther. 2014 Mar; 16(3):125-30.
    View in: PubMed
    Score: 0.197
  21. Garg SK. Standardization of self-monitoring of blood glucose and continuous glucose monitoring reporting. Diabetes Technol Ther. 2013 Mar; 15(3):193.
    View in: PubMed
    Score: 0.186
  22. Moser EG, Morris AA, Garg SK. Emerging diabetes therapies and technologies. Diabetes Res Clin Pract. 2012 Jul; 97(1):16-26.
    View in: PubMed
    Score: 0.173
  23. Misra A, Garg S. HbA1c and blood glucose for the diagnosis of diabetes. Lancet. 2011 Jul 09; 378(9786):104-6.
    View in: PubMed
    Score: 0.165
  24. Garg SK, Voelmle M, Gottlieb PA. Time lag characterization of two continuous glucose monitoring systems. Diabetes Res Clin Pract. 2010 Mar; 87(3):348-53.
    View in: PubMed
    Score: 0.151
  25. Rodbard D, Jovanovic L, Garg SK. Responses to continuous glucose monitoring in subjects with type 1 diabetes using continuous subcutaneous insulin infusion or multiple daily injections. Diabetes Technol Ther. 2009 Dec; 11(12):757-65.
    View in: PubMed
    Score: 0.148
  26. Rodbard D, Bailey T, Jovanovic L, Zisser H, Kaplan R, Garg SK. Improved quality of glycemic control and reduced glycemic variability with use of continuous glucose monitoring. Diabetes Technol Ther. 2009 Nov; 11(11):717-23.
    View in: PubMed
    Score: 0.148
  27. Garg SK. The future of continuous glucose monitoring. Diabetes Technol Ther. 2009 Jun; 11 Suppl 1:S1-3.
    View in: PubMed
    Score: 0.143
  28. Garg SK, Voelmle MK, Gottlieb P. Feasibility of 10-day use of a continuous glucose-monitoring system in adults with type 1 diabetes. Diabetes Care. 2009 Mar; 32(3):436-8.
    View in: PubMed
    Score: 0.138
  29. Garg SK, Bookout TR, McFann KK, Kelly WC, Beatson C, Ellis SL, Gutin RS, Gottlieb PA. Improved glycemic control in intensively treated adult subjects with type 1 diabetes using insulin guidance software. Diabetes Technol Ther. 2008 Oct; 10(5):369-75.
    View in: PubMed
    Score: 0.137
  30. Ellis SL, Naik RG, Gemperline K, Garg SK. Use of continuous glucose monitoring in patients with type 1 diabetes. Curr Diabetes Rev. 2008 Aug; 4(3):207-17.
    View in: PubMed
    Score: 0.135
  31. Garg SK, Kelly WC, Voelmle MK, Ritchie PJ, Gottlieb PA, McFann KK, Ellis SL. Continuous home monitoring of glucose: improved glycemic control with real-life use of continuous glucose sensors in adult subjects with type 1 diabetes. Diabetes Care. 2007 Dec; 30(12):3023-5.
    View in: PubMed
    Score: 0.127
  32. Ellis SL, Gemperline KA, Garg SK. Review of phase 2 studies utilizing the AIR particle technology in the delivery of human insulin inhalation powder versus subcutaneous regular or lispro insulin in subjects with type 1 or type 2 diabetes. Diabetes Technol Ther. 2007 Jun; 9 Suppl 1:S48-56.
    View in: PubMed
    Score: 0.125
  33. Garg S, Jovanovic L. Relationship of fasting and hourly blood glucose levels to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Diabetes Care. 2006 Dec; 29(12):2644-9.
    View in: PubMed
    Score: 0.121
  34. Akturk HK, Mason E, Cengiz D, Karakus KE, Garg SK. Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2026 Jun; 28(6):614-618.
    View in: PubMed
    Score: 0.115
  35. Nally LM, Sherr JL, Garg SK, Marks BE, Laffel LM, Pihoker C, Accacha SD, Thrasher JR, Abuzzahab MJ, Reed JH, Ekhlaspour L, Belapurkar S, Shulman DI, Sunil B, MacLeish SA, Latif K, Forlenza GP, Castorino K, Lal RA, Bode BW, Broyles FE, Carlson AL, Nwosu BU, Shin J, Ma H, Salbato A, Cordero TL, Treminio Y, McVean JJ, Rhinehart AS, Vigersky RA. Safety and Glycemic Outcomes of the MiniMed 780G System with a Disposable All-in-One Sensor. Diabetes Technol Ther. 2026 Feb; 28(2):109-120.
    View in: PubMed
    Score: 0.114
  36. Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, Jovanovic L. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006 Jan; 29(1):44-50.
    View in: PubMed
    Score: 0.113
  37. Hirsch IB, Garg SK, Repetto E, Snell-Bergeon J, Ulmer B, Perkins C, Bergenstal RM. Continuous Glucose Monitoring Frequency and Glycemic Control in People With Type 2 Diabetes. JAMA Netw Open. 2025 10 01; 8(10):e2539278.
    View in: PubMed
    Score: 0.111
  38. Akturk HK, Brown SA, Beck RW, Sherr JL, Bergenstal RM, Kovatchev BP, Vigersky R, Breton MD, Hovorka R, Klonoff DC, Garg SK. Registration and Real-Life Studies on Automated Insulin Delivery Systems. J Diabetes Sci Technol. 2025 07; 19(4):924-936.
    View in: PubMed
    Score: 0.109
  39. Akturk HK, Brown SA, Beck RW, Sherr JL, Bergenstal RM, Kovatchev BP, Vigersky R, Breton MD, Hovorka R, Klonoff DC, Garg SK. Registration and Real-Life Studies on Automated Insulin Delivery Systems. Diabetes Technol Ther. 2025 07; 27(S3):S48-S59.
    View in: PubMed
    Score: 0.109
  40. Garg SK, Kaur G, Renner D, Lanning MS, Mason E, Beatson C, Ciesco K, Snell-Bergeon J. Cardiovascular and Renal Biomarkers in Overweight and Obese Adults with Type 1 Diabetes Treated with Tirzepatide for 21 Months. Diabetes Technol Ther. 2025 03; 27(3):152-160.
    View in: PubMed
    Score: 0.107
  41. Snell-Bergeon JK, Kaur G, Renner D, Akturk HK, Beatson C, Garg SK. Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes. Diabetes Technol Ther. 2025 01; 27(1):1-9.
    View in: PubMed
    Score: 0.106
  42. Garg SK, Gottlieb PA, Hisatomi ME, D'Souza A, Walker AJ, Izuora KE, Chase HP. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract. 2004 Oct; 66(1):49-56.
    View in: PubMed
    Score: 0.104
  43. Garg SK. Health impact from frequent and continuous glucose monitoring. Diabetes Technol Ther. 2004 Aug; 6(4):523-4.
    View in: PubMed
    Score: 0.103
  44. Boeder S, Davies MJ, McGill JB, Pratley R, Girard M, Banks P, Pettus J, Garg S. Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin. Diabetes Technol Ther. 2024 09; 26(9):618-625.
    View in: PubMed
    Score: 0.101
  45. Garg SK, Schwartz S, Edelman SV. Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care. 2004 Mar; 27(3):734-8.
    View in: PubMed
    Score: 0.100
  46. Garg SK, McVean JJ. Development and Future of Automated Insulin Delivery (AID) Systems. Diabetes Technol Ther. 2024 03; 26(S3):1-6.
    View in: PubMed
    Score: 0.100
  47. Bailey R, Calhoun P, Garg SK. Weight Gain and Glycemic Control in Adults with Type 1 Diabetes in the T1D Exchange Registry. Diabetes Technol Ther. 2024 03; 26(3):156-160.
    View in: PubMed
    Score: 0.100
  48. Garg SK, Polsky S. Technology Use and Glycemic Outcomes during Pregnancy with Type 1 Diabetes. N Engl J Med. 2023 10 26; 389(17):1617-1619.
    View in: PubMed
    Score: 0.097
  49. Chase HP, Pearson JA, Wightman C, Roberts MD, Oderberg AD, Garg SK. Modem transmission of glucose values reduces the costs and need for clinic visits. Diabetes Care. 2003 May; 26(5):1475-9.
    View in: PubMed
    Score: 0.094
  50. Garg SK, Frias JP, Anil S, Gottlieb PA, MacKenzie T, Jackson WE. Insulin lispro therapy in pregnancies complicated by type 1 diabetes: glycemic control and maternal and fetal outcomes. Endocr Pract. 2003 May-Jun; 9(3):187-93.
    View in: PubMed
    Score: 0.094
  51. Garg SK, Grunberger G, Weinstock R, Lawson ML, Hirsch IB, DiMeglio LA, Pop-Busui R, Philis-Tsimikas A, Kipnes M, Liljenquist DR, Brazg RL, Kudva YC, Buckingham BA, McGill JB, Carlson AL, Criego AB, Christiansen MP, Kaiserman KB, Griffin KJ, Forlenza GP, Bode BW, Slover RH, Keiter A, Ling C, Marinos B, Cordero TL, Shin J, Lee SW, Rhinehart AS, Vigersky RA. Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial. Diabetes Technol Ther. 2023 01; 25(1):1-12.
    View in: PubMed
    Score: 0.092
  52. Garg SK, Kipnes M, Castorino K, Bailey TS, Akturk HK, Welsh JB, Christiansen MP, Balo AK, Brown SA, Reid JL, Beck SE. Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes. Diabetes Technol Ther. 2022 06; 24(6):373-380.
    View in: PubMed
    Score: 0.087
  53. Garg SK, Liljenquist D, Bode B, Christiansen MP, Bailey TS, Brazg RL, Denham DS, Chang AR, Akturk HK, Dehennis A, Tweden KS, Kaufman FR. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technol Ther. 2022 02; 24(2):84-92.
    View in: PubMed
    Score: 0.084
  54. Garg SK. Emerging Landscape of Continuous Glucose Monitoring. Diabetes Technol Ther. 2021 09; 23(S3):S1-S4.
    View in: PubMed
    Score: 0.084
  55. Rodbard D, Garg SK. Standardizing Reporting of Glucose and Insulin Data for Patients on Multiple Daily Injections Using Connected Insulin Pens and Continuous Glucose Monitoring. Diabetes Technol Ther. 2021 03; 23(3):221-226.
    View in: PubMed
    Score: 0.081
  56. Rodbard HW, Giaccari A, Cariou B, Garg S, Davies MJ, Seth K, Sawhney S. Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2. Diab Vasc Dis Res. 2021 Jan-Feb; 18(1):1479164121995928.
    View in: PubMed
    Score: 0.080
  57. Shah VN, Garg SK. Standardized Hybrid Closed-Loop System Reporting. Diabetes Technol Ther. 2021 05; 23(5):323-331.
    View in: PubMed
    Score: 0.079
  58. Garg SK, Wernicke-Panten K, Wardecki M, Kramer D, Delalande F, Franek E, Sadeharju K, Monchamp T, Miossec P, Mukherjee B, Shah VN. Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial. Diabetes Technol Ther. 2020 07; 22(7):516-526.
    View in: PubMed
    Score: 0.076
  59. Garg SK, Wernicke-Panten K, Wardecki M, Kramer D, Delalande F, Franek E, Sadeharju K, Monchamp T, Mukherjee B, Shah VN. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1). Diabetes Technol Ther. 2020 02; 22(2):85-95.
    View in: PubMed
    Score: 0.075
  60. Garg SK, Brackett S, Reinicke T, Hirsch IB. New Medications for the Treatment of Diabetes. Diabetes Technol Ther. 2020 Feb; 22(S1):S149-S173.
    View in: PubMed
    Score: 0.075
  61. Thrasher J, Polsky S, Hovsepian L, Nowotny I, Pierre S, Bois De Fer B, Bhargava A, Mukherjee B, Garg SK. Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial. Diabetes Technol Ther. 2020 09; 22(9):666-673.
    View in: PubMed
    Score: 0.075
  62. Danne T, Pettus J, Giaccari A, Cariou B, Rodbard H, Weinzimer SA, Bonnemaire M, Sawhney S, Stewart J, Wang S, Castro RC, Garg SK. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2019 09; 21(9):471-477.
    View in: PubMed
    Score: 0.073
  63. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Nørgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019 08; 42(8):1593-1603.
    View in: PubMed
    Score: 0.072
  64. Danne T, Cariou B, Buse JB, Garg SK, Rosenstock J, Banks P, Kushner JA, McGuire DK, Peters AL, Sawhney S, Strumph P. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. Diabetes Care. 2019 05; 42(5):919-930.
    View in: PubMed
    Score: 0.070
  65. Garg SK, Giordano D. New Medications for the Treatment of Diabetes. Diabetes Technol Ther. 2019 02; 21(S1):S160-S171.
    View in: PubMed
    Score: 0.070
  66. Akturk HK, Rewers A, Garg SK. SGLT inhibition: a possible adjunctive treatment for type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2018 08; 25(4):246-250.
    View in: PubMed
    Score: 0.068
  67. Garg SK, Strumph P. Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes. N Engl J Med. 2018 03 08; 378(10):967-968.
    View in: PubMed
    Score: 0.066
  68. Home P, Derwahl KM, Ziemen M, Wernicke-Panten K, Pierre S, Kirchhein Y, Garg SK. Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes. Diabetes Technol Ther. 2018 02; 20(2):160-170.
    View in: PubMed
    Score: 0.065
  69. Garg SK, Polsky S. Continuous glucose monitoring in pregnant women with type 1 diabetes. Lancet. 2017 11 25; 390(10110):2329-2331.
    View in: PubMed
    Score: 0.064
  70. Garg SK, Wernicke-Panten K, Rojeski M, Pierre S, Kirchhein Y, Jedynasty K. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study. Diabetes Technol Ther. 2017 09; 19(9):516-526.
    View in: PubMed
    Score: 0.063
  71. Christiansen MP, Garg SK, Brazg R, Bode BW, Bailey TS, Slover RH, Sullivan A, Huang S, Shin J, Lee SW, Kaufman FR. Accuracy of a Fourth-Generation Subcutaneous Continuous Glucose Sensor. Diabetes Technol Ther. 2017 08; 19(8):446-456.
    View in: PubMed
    Score: 0.063
  72. Schnell O, Barnard K, Bergenstal R, Bosi E, Garg S, Guerci B, Haak T, Hirsch IB, Ji L, Joshi SR, Kamp M, Laffel L, Mathieu C, Polonsky WH, Snoek F, Home P. Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. Diabetes Technol Ther. 2017 07; 19(7):391-399.
    View in: PubMed
    Score: 0.062
  73. Ji L, Zhang P, Zhu D, Li X, Ji J, Lu J, Guo X, Jia W, Weng J, Wu Y, Yang W, Zou D, Zhou Z, Pan C, Gao Y, Garg SK. Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in China. Diabetes Obes Metab. 2017 06; 19(6):822-830.
    View in: PubMed
    Score: 0.061
  74. Buckingham BA, Bailey TS, Christiansen M, Garg S, Weinzimer S, Bode B, Anderson SM, Brazg R, Ly TT, Kaufman FR. Evaluation of a Predictive Low-Glucose Management System In-Clinic. Diabetes Technol Ther. 2017 05; 19(5):288-292.
    View in: PubMed
    Score: 0.061
  75. Polsky S, Giordano D, Voelmle MK, Garcetti R, Garg SK. Using technology to advance type 1 diabetes care among women during the reproductive years and in pregnancy. Postgrad Med. 2016 May; 128(4):418-26.
    View in: PubMed
    Score: 0.057
  76. Garg SK, Hirsch IB. Self-Monitoring of Blood Glucose. Diabetes Technol Ther. 2016 Feb; 18 Suppl 1:S3-9.
    View in: PubMed
    Score: 0.057
  77. Schnell O, Barnard K, Bergenstal R, Bosi E, Garg S, Guerci B, Haak T, Hirsch IB, Ji L, Joshi SR, Kamp M, Laffel L, Mathieu C, Polonsky WH, Snoek F, Home P. Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research. Diabetes Care. 2015 Sep; 38(9):1627-33.
    View in: PubMed
    Score: 0.055
  78. Ji L, Zhang P, Weng J, Lu J, Guo X, Jia W, Yang W, Zou D, Zhou Z, Pan C, Gao Y, Li X, Zhu D, Li Y, Wu Y, Garg SK. Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China--Study Design and Baseline Characteristics. Diabetes Technol Ther. 2015 Oct; 17(10):735-44.
    View in: PubMed
    Score: 0.055
  79. Weiss R, Garg SK, Bergenstal RM, Klonoff DC, Bode BW, Bailey TS, Thrasher J, Schwartz F, Welsh JB, Kaufman FR. Predictors of Hypoglycemia in the ASPIRE In-Home Study and Effects of Automatic Suspension of Insulin Delivery. J Diabetes Sci Technol. 2015 May 18; 9(5):1016-20.
    View in: PubMed
    Score: 0.054
  80. Garg SK, Admane K, Freemantle N, Odawara M, Pan CY, Misra A, Jarek-Martynowa IR, Abbas-Raza S, Mirasol RC, Perfetti R. Patient-led versus physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational ATLAS study. Endocr Pract. 2015 Feb; 21(2):143-57.
    View in: PubMed
    Score: 0.053
  81. Shah VN, Shoskes A, Tawfik B, Garg SK. Closed-loop system in the management of diabetes: past, present, and future. Diabetes Technol Ther. 2014 Aug; 16(8):477-90.
    View in: PubMed
    Score: 0.051
  82. Bailey TS, Ahmann A, Brazg R, Christiansen M, Garg S, Watkins E, Welsh JB, Lee SW. Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor. Diabetes Technol Ther. 2014 May; 16(5):277-83.
    View in: PubMed
    Score: 0.050
  83. Garg SK, Aurand LA, Rimler MS, Dailey GE. Diabetes duration and the efficacy and safety of insulin glargine versus comparator treatment in patients with type 2 diabetes mellitus. Endocr Pract. 2014 Feb; 20(2):120-8.
    View in: PubMed
    Score: 0.050
  84. Ahmann A, Szeinbach SL, Gill J, Traylor L, Garg SK. Comparing patient preferences and healthcare provider recommendations with the pen versus vial-and-syringe insulin delivery in patients with type 2 diabetes. Diabetes Technol Ther. 2014 Feb; 16(2):76-83.
    View in: PubMed
    Score: 0.049
  85. Garg SK, Michels AW, Shah VN. Use of non-insulin therapies for type 1 diabetes. Diabetes Technol Ther. 2013 Nov; 15(11):901-8.
    View in: PubMed
    Score: 0.049
  86. Bergenstal RM, Ahmann AJ, Bailey T, Beck RW, Bissen J, Buckingham B, Deeb L, Dolin RH, Garg SK, Goland R, Hirsch IB, Klonoff DC, Kruger DF, Matfin G, Mazze RS, Olson BA, Parkin C, Peters A, Powers MA, Rodriguez H, Southerland P, Strock ES, Tamborlane W, Wesley DM. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. J Diabetes Sci Technol. 2013 Mar 01; 7(2):562-78.
    View in: PubMed
    Score: 0.046
  87. Bergenstal RM, Ahmann AJ, Bailey T, Beck RW, Bissen J, Buckingham B, Deeb L, Dolin RH, Garg SK, Goland R, Hirsch IB, Klonoff DC, Kruger DF, Matfin G, Mazze RS, Olson BA, Parkin C, Peters A, Powers MA, Rodriguez H, Southerland P, Strock ES, Tamborlane W, Wesley DM. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther. 2013 Mar; 15(3):198-211.
    View in: PubMed
    Score: 0.046
  88. Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, Snell-Bergeon JK. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract. 2013 Jan-Feb; 19(1):19-28.
    View in: PubMed
    Score: 0.046
  89. Switzer SM, Moser EG, Rockler BE, Garg SK. Intensive insulin therapy in patients with type 1 diabetes mellitus. Endocrinol Metab Clin North Am. 2012 Mar; 41(1):89-104.
    View in: PubMed
    Score: 0.044
  90. Garg S, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, Shin J, Welsh JB, Kaufman FR. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes Technol Ther. 2012 Mar; 14(3):205-9.
    View in: PubMed
    Score: 0.043
  91. Garg SK, Voelmle MK, Beatson CR, Miller HA, Crew LB, Freson BJ, Hazenfield RM. Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study. Diabetes Care. 2011 Mar; 34(3):574-9.
    View in: PubMed
    Score: 0.040
  92. Blevins TC, Bode BW, Garg SK, Grunberger G, Hirsch IB, Jovanovic L, Nardacci E, Orzeck EA, Roberts VL, Tamborlane WV, Rothermel C. Statement by the American Association of Clinical Endocrinologists Consensus Panel on continuous glucose monitoring. Endocr Pract. 2010 Sep-Oct; 16(5):730-45.
    View in: PubMed
    Score: 0.039
  93. Garg SK, Mathieu C, Rais N, Gao H, Tobian JA, Gates JR, Ferguson JA, Webb DM, Berclaz PY. Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: An open-label randomized controlled trial. Diabetes Technol Ther. 2009 Sep; 11 Suppl 2:S5-S16.
    View in: PubMed
    Score: 0.036
  94. Garg SK, Smith J, Beatson C, Lopez-Baca B, Voelmle M, Gottlieb PA. Comparison of accuracy and safety of the SEVEN and the Navigator continuous glucose monitoring systems. Diabetes Technol Ther. 2009 Feb; 11(2):65-72.
    View in: PubMed
    Score: 0.035
  95. Garg SK. Role of emerging new technologies. Diabetes Technol Ther. 2008 Oct; 10(5):413-4.
    View in: PubMed
    Score: 0.034
  96. Ulrich H, Snyder B, Garg SK. Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine. Vasc Health Risk Manag. 2007; 3(3):245-54.
    View in: PubMed
    Score: 0.030
  97. Jendle JH, Garg SK, Thivolet C, Weinstock RS, Hirsch IB, Evans M, Griffin KJ, Philis-Tsimikas A, Wheeler BJ, Kipnes MS, Carlson AL, Buckingham BA, Bhargava A, Bode BW, Lawson ML, Criego AB, McGill JB, Reed JCH, Prakasam G, Grunberger G, Girelli A, Martinez-Brocca MA, Christiansen MP, de Bock MI, Kudva YC, Lee SW, Yovanovich C, Shin JJ, Cordero TL, McVean JJF, Vigersky RA. Automated basal insulin delivery versus multiple daily injections in type 1 diabetes: results from a randomized parallel controlled trial. Front Endocrinol (Lausanne). 2025; 16:1716587.
    View in: PubMed
    Score: 0.028
  98. Garg S, Chase HP. Treatment of adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2004 May; 17(5):805-6.
    View in: PubMed
    Score: 0.025
  99. Weinzimer SA, Tamborlane WV, Chase HP, Garg SK. Continuous glucose monitoring in type 1 diabetes. Curr Diab Rep. 2004 Apr; 4(2):95-100.
    View in: PubMed
    Score: 0.025
  100. Phillip M, Nimri R, Bergenstal RM, Barnard-Kelly K, Danne T, Hovorka R, Kovatchev BP, Messer LH, Parkin CG, Ambler-Osborn L, Amiel SA, Bally L, Beck RW, Biester S, Biester T, Blanchette JE, Bosi E, Boughton CK, Breton MD, Brown SA, Buckingham BA, Cai A, Carlson AL, Castle JR, Choudhary P, Close KL, Cobelli C, Criego AB, Davis E, de Beaufort C, de Bock MI, DeSalvo DJ, DeVries JH, Dovc K, Doyle FJ, Ekhlaspour L, Shvalb NF, Forlenza GP, Gallen G, Garg SK, Gershenoff DC, Gonder-Frederick LA, Haidar A, Hartnell S, Heinemann L, Heller S, Hirsch IB, Hood KK, Isaacs D, Klonoff DC, Kordonouri O, Kowalski A, Laffel L, Lawton J, Lal RA, Leelarathna L, Maahs DM, Murphy HR, Nørgaard K, O'Neal D, Oser S, Oser T, Renard E, Riddell MC, Rodbard D, Russell SJ, Schatz DA, Shah VN, Sherr JL, Simonson GD, Wadwa RP, Ward C, Weinzimer SA, Wilmot EG, Battelino T. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. Endocr Rev. 2023 03 04; 44(2):254-280.
    View in: PubMed
    Score: 0.023
  101. Battelino T, Alexander CM, Amiel SA, Arreaza-Rubin G, Beck RW, Bergenstal RM, Buckingham BA, Carroll J, Ceriello A, Chow E, Choudhary P, Close K, Danne T, Dutta S, Gabbay R, Garg S, Heverly J, Hirsch IB, Kader T, Kenney J, Kovatchev B, Laffel L, Maahs D, Mathieu C, Mauricio D, Nimri R, Nishimura R, Scharf M, Del Prato S, Renard E, Rosenstock J, Saboo B, Ueki K, Umpierrez GE, Weinzimer SA, Phillip M. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol. 2023 01; 11(1):42-57.
    View in: PubMed
    Score: 0.023
  102. Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, Klaff LJ, Rosenstock J, Cheng MHM, Bode BW, Bautista ED, Xu R, Yan H, Thai D, Garg SK, Klein S. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med. 2022 10; 28(10):2092-2099.
    View in: PubMed
    Score: 0.023
  103. Weinstock RS, Bode BW, Garg SK, Klonoff DC, El Sanadi C, Geho WB, Muchmore DB, Penn MS. Reduced hypoglycaemia using liver-targeted insulin in individuals with type 1 diabetes. Diabetes Obes Metab. 2022 09; 24(9):1762-1769.
    View in: PubMed
    Score: 0.022
  104. Brazg R, Garg SK, Bhargava A, Thrasher JR, Latif K, Bode BW, Bailey TS, Horowitz BS, Cavale A, Kudva YC, Kaiserman KB, Grunberger G, Reed JC, Chattaraj S, Zhang G, Shin J, Chen V, Lee SW, Cordero TL, Rhinehart AS, Vigersky RA, Buckingham BA. Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial. Diabetes Technol Ther. 2022 08; 24(8):535-543.
    View in: PubMed
    Score: 0.022
  105. Carlson AL, Sherr JL, Shulman DI, Garg SK, Pop-Busui R, Bode BW, Lilenquist DR, Brazg RL, Kaiserman KB, Kipnes MS, Thrasher JR, Reed JHC, Slover RH, Philis-Tsimikas A, Christiansen M, Grosman B, Roy A, Vella M, Jonkers RAM, Chen X, Shin J, Cordero TL, Lee SW, Rhinehart AS, Vigersky RA. Safety and Glycemic Outcomes During the MiniMed? Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2022 03; 24(3):178-189.
    View in: PubMed
    Score: 0.021
  106. Bode BW, Garg SK, Norwood P, Morales C, Hardy T, Liu R, Ignaut D. Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study. Diabetes Technol Ther. 2021 01; 23(1):41-50.
    View in: PubMed
    Score: 0.019
  107. Gao L, Zhang P, Weng J, Lu J, Guo X, Jia W, Yang W, Zou D, Zhou Z, Pan C, Gao Y, Li X, Zhu D, Wu Y, Garg SK, Ji L. Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT). J Diabetes. 2020 Sep; 12(9):668-676.
    View in: PubMed
    Score: 0.019
  108. DeSouza C, Cariou B, Garg S, Lausvig N, Navarria A, Fonseca V. Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials. J Clin Endocrinol Metab. 2020 02 01; 105(2).
    View in: PubMed
    Score: 0.019
  109. Akturk HK, Giordano D, Champakanath A, Brackett S, Garg S, Snell-Bergeon J. Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes. Diabetes Obes Metab. 2020 04; 22(4):583-589.
    View in: PubMed
    Score: 0.019
  110. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, Nørgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017 12; 40(12):1631-1640.
    View in: PubMed
    Score: 0.016
  111. Cordero TL, Garg SK, Brazg R, Bailey TS, Shin J, Lee SW, Kaufman FR. The Effect of Prior Continuous Glucose Monitoring Use on Glycemic Outcomes in the Pivotal Trial of the MiniMed? 670G Hybrid Closed-Loop System. Diabetes Technol Ther. 2017 Dec; 19(12):749-752.
    View in: PubMed
    Score: 0.016
  112. Bergenstal RM, Garg S, Weinzimer SA, Buckingham BA, Bode BW, Tamborlane WV, Kaufman FR. Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. JAMA. 2016 10 04; 316(13):1407-1408.
    View in: PubMed
    Score: 0.015
  113. Weinstock RS, DuBose SN, Bergenstal RM, Chaytor NS, Peterson C, Olson BA, Munshi MN, Perrin AJ, Miller KM, Beck RW, Liljenquist DR, Aleppo G, Buse JB, Kruger D, Bhargava A, Goland RS, Edelen RC, Pratley RE, Peters AL, Rodriguez H, Ahmann AJ, Lock JP, Garg SK, Rickels MR, Hirsch IB. Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. Diabetes Care. 2016 Apr; 39(4):603-10.
    View in: PubMed
    Score: 0.014
  114. Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, Buse JB, Banks P, Heptulla R, Rendell M, Cefalu WT, Strumph P. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Diabetes Care. 2015 Jul; 38(7):1181-8.
    View in: PubMed
    Score: 0.014
  115. Weiss R, Garg SK, Bode BW, Bailey TS, Ahmann AJ, Schultz KA, Welsh JB, Shin JJ. Hypoglycemia Reduction and Changes in Hemoglobin A1c in the ASPIRE In-Home Study. Diabetes Technol Ther. 2015 Aug; 17(8):542-7.
    View in: PubMed
    Score: 0.014
  116. Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, Ahmann AJ, Welsh JB, Lee SW, Kaufman FR. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013 Jul 18; 369(3):224-32.
    View in: PubMed
    Score: 0.012
  117. Brazg RL, Bailey TS, Garg S, Buckingham BA, Slover RH, Klonoff DC, Nguyen X, Shin J, Welsh JB, Lee SW. The ASPIRE study: design and methods of an in-clinic crossover trial on the efficacy of automatic insulin pump suspension in exercise-induced hypoglycemia. J Diabetes Sci Technol. 2011 Nov 01; 5(6):1466-71.
    View in: PubMed
    Score: 0.011
  118. Ellis SL, Bookout T, Garg SK, Izuora KE. Use of continuous glucose monitoring to improve diabetes mellitus management. Endocrinol Metab Clin North Am. 2007 Dec; 36 Suppl 2:46-68.
    View in: PubMed
    Score: 0.008
  119. Edelman SV, Garg S, Kolterman OG. Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes? Nat Clin Pract Endocrinol Metab. 2007 May; 3(5):E1; discussion E2.
    View in: PubMed
    Score: 0.008
  120. Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, Strobel S, Lutz K, Kolterman O. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006 Oct; 29(10):2189-95.
    View in: PubMed
    Score: 0.007
  121. Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care. 2005 Mar; 28(3):533-8.
    View in: PubMed
    Score: 0.007
  122. Snell-Bergeon JK, Hokanson JE, Jensen L, MacKenzie T, Kinney G, Dabelea D, Eckel RH, Ehrlich J, Garg S, Rewers M. Progression of coronary artery calcification in type 1 diabetes: the importance of glycemic control. Diabetes Care. 2003 Oct; 26(10):2923-8.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)